Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Bad Vöslau – page 29

865 clinical trials in Bad Vöslau, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Bad Vöslau at a glance
865
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

865 trials in Bad Vöslau

Open in trial search

Study of Dasatinib and Venetoclax for Children with Relapsed or Refractory Leukemia or Lymphoma with MAPK/SRC Pathway Mutation

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Dasatinib
  • Sponsor:Prinses Maxima Centrum voor Kinderoncologie B.V.

Study on Ketamine and Midazolam for Treating Obsessive-Compulsive Disorder in Adults

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:Ketamine
  • Sponsor:Medical University Of Vienna

Crohn's disease

Recruiting

Study of Lutikizumab, ABBV-382, and Risankizumab for Adults with Moderate to Severe Crohn's Disease

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:ABBV-8736
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Dermatitis atopic

Not yet recruiting

Efficacy and Safety of Rezpegaldesleukin (NKTR-358) in Patients Aged 12 Years and Older with Moderate-to-Severe Atopic Dermatitis

Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Rezpegaldesleukin
  • Sponsor:Nektar Therapeutics

Ovarian cancer

Not yet recruiting

Study of gsk5733584 with bevacizumab versus standard drug combination in patients with platinum-sensitive ovarian cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Pruritus

Not yet recruiting

Efficacy and safety of remibrutinib, tacrolimus and pimecrolimus in adults with severe chronic pruritus of unknown origin: a randomized, placebo‑controlled trial

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Pimecrolimus
  • Sponsor:Novartis Pharma AG

Systemic scleroderma+2

Not yet recruiting

Long‑term Safety and Tolerability of Anifrolumab in Adults with Systemic Lupus Erythematosus Who Completed Prior Study

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Anifrolumab
  • Sponsor:Astrazeneca AB

Efficacy and Safety of Atumelnant, Hydrocortisone and Prednisone in Adults with ACTH‑Dependent Cushing’s Syndrome: A Phase 2/3 Dose‑Finding Study

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Atumelnant
  • Sponsor:Crinetics Pharmaceuticals Inc.

Aortic valve stenosis

Not yet recruiting

A Phase 2b/3 Randomized Double‑Blind Study of Ataciguat to Slow Disease Progression in Adults with Moderate Calcific Aortic Valve Stenosis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ataciguat
  • Sponsor:Kardigan Inc.

Arteriosclerosis

Not yet recruiting

A study to evaluate the effect of muvalaplin on reducing major cardiovascular events in adults with high levels of lipoprotein(a) and atherosclerotic cardiovascular disease.

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Muvalaplin
  • Sponsor:Eli Lilly & Co.

Arteriosclerosis

Not yet recruiting

Study of olpasiran to prevent first major cardiovascular events in people with high levels of lipoprotein(a)

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Olpasiran
  • Sponsor:Amgen Inc.

Partial seizures

Not yet recruiting

Study on the Effectiveness and Safety of BHV-7000 for Adults with Refractory Focal Onset Epilepsy

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:BHV-7000
  • Sponsor:Biohaven Therapeutics Ltd.

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Bad Vöslau

What the registry says about research in the country

01 Neuropathic Pain Studies

Investigating new treatment approaches for patients with diabetic polyneuropathy, focusing on innovative pain management solutions that could improve quality of life for those affected by chronic neuropathic conditions.

  • Diabetic Neuropathy Management
  • Chronic Pain Treatment
  • Add-on Therapy Evaluation

Research aims to enhance current treatment protocols for diabetes-related nerve pain.

02 Trauma-Related Neuropathy

Evaluating therapeutic options for patients experiencing post-operative and traumatic peripheral neuropathy, with a focus on developing effective pain management strategies for those affected by surgery or injury-related nerve damage.

  • Post-surgical Pain Management
  • Trauma-induced Neuropathy
  • Peripheral Nerve Pain

Studies explore innovative approaches to managing chronic pain resulting from surgical procedures and trauma.

03 Central Neuropathy Research

Examining treatment efficacy for central neuropathy of various origins, investigating novel therapeutic approaches for managing chronic pain associated with central nervous system conditions.

  • Central Nervous System Pain
  • Neurological Pain Management
  • Pain Relief Strategies

This research explores comprehensive treatment options for central nervous system-related pain conditions.

04 Chronic Back Pain Treatment

Investigating innovative therapies for patients suffering from chronic back pain, focusing on developing effective add-on treatments to enhance current pain management approaches.

  • Back Pain Management
  • Long-term Pain Relief
  • Therapeutic Advancement

Studies aim to improve treatment outcomes for individuals with persistent back pain conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.